Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

Vizient, Inc. released its new Spend Management Outlook representing the best estimate of the change in the price of pharmaceuticals, medical devices and supplies, capital equipment and services ...

account for 54% of total drug spending in the U.S., according to IQVIA. Humira®, STELARA® (Janssen Biotech) and SKYRIZI® (AbbVie) are projected to have the largest price increases for the ...

In last week’s Sunday Digest, I (Tom Yeung) wrote how cyclical companies are often incredible investments. Firms like copper ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. released its new Spend Management Outlook representing the best estimate of the change in the price of pharmaceuticals, medical devices and supplies, ...

Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts. Invest with ...

AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded ...

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to ...

The following bupropion dosage chart highlights the basics, including the typical starting dose and the maximum or largest dose of bupropion per day. All doses are listed in milligrams (mg).

For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulation of Humira ...

Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.